RAFAEL HOLDINGS, INC. Proceeds from Sale of Held-to-maturity Securities
RAFAEL HOLDINGS, INC. (RFL) reported Proceeds from Sale of Held-to-maturity Securities of $80.69 million for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for the quarter ending 2025-07-31 was $0.00, a 100.00% decline year-over-year.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for the quarter ending 2025-04-30 was $0.00, a 100.00% decline year-over-year.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for the quarter ending 2025-01-31 was $47.38M, a 9.98% decline year-over-year.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for the quarter ending 2024-10-31 was $33.32M, a 29.80% decline year-over-year.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for fiscal 2025 was $80.69M, a 47.38% decline from fiscal 2024.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for fiscal 2024 was $153.35M, a 17.16% decline from fiscal 2023.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for fiscal 2023 was $185.12M, a 549.55% increase from fiscal 2022.
- RAFAEL HOLDINGS, INC. proceeds from sale of held-to-maturity securities for fiscal 2022 was $28.50M.
| Period end | Proceeds from Sale of Held-to-maturity Securities 3 month | Proceeds from Sale of Held-to-maturity Securities 6 month | Proceeds from Sale of Held-to-maturity Securities 9 month | Proceeds from Sale of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2025-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $47.38M derived: sum of 3 quarters · filed 2025-10-29 | $80.69M 10-K · filed 2025-10-29 |
| 2025-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | $47.38M derived: sum of 2 quarters · filed 2025-06-11 | $80.69M 10-Q · filed 2025-06-11 | $105.02M derived: sum of 4 quarters · filed 2025-10-29 |
| 2025-01-31 | $47.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | $80.69M 10-Q · filed 2025-03-14 | $105.02M derived: sum of 3 quarters · filed 2025-10-29 | $133.96M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-10-31 | $33.32M 10-Q · filed 2024-12-11 | $57.65M derived: sum of 2 quarters · filed 2025-10-29 | $86.58M derived: sum of 3 quarters · filed 2025-10-29 | $139.21M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-07-31 | $24.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $53.26M derived: sum of 2 quarters · filed 2025-10-29 | $105.89M derived: sum of 3 quarters · filed 2025-10-29 | $153.35M 10-K · filed 2025-10-29 |
| 2024-04-30 | $28.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | $81.56M derived: sum of 2 quarters · filed 2025-06-11 | $129.02M 10-Q · filed 2025-06-11 | $177.17M derived: sum of 4 quarters · filed 2025-06-11 |
| 2024-01-31 | $52.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14 | $100.09M 10-Q · filed 2025-03-14 | $148.24M derived: sum of 3 quarters · filed 2025-03-14 | $213.83M derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-10-31 | $47.46M 10-Q · filed 2024-12-11 | $95.61M derived: sum of 2 quarters · filed 2024-12-20 | $161.20M derived: sum of 3 quarters · filed 2024-12-20 | $209.66M derived: sum of 4 quarters · filed 2024-12-20 |
| 2023-07-31 | $48.15M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $113.74M derived: sum of 2 quarters · filed 2024-12-20 | $162.20M derived: sum of 3 quarters · filed 2024-12-20 | $185.12M 10-K/A · filed 2024-12-20 |
| 2023-04-30 | $65.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $114.05M derived: sum of 2 quarters · filed 2024-06-14 | $136.97M 10-Q · filed 2024-06-14 | |
| 2023-01-31 | $48.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | $71.38M 10-Q · filed 2024-03-14 | ||
| 2022-10-31 | $22.92M 10-Q · filed 2023-12-14 | |||
| 2022-07-31 | $28.50M 10-K · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |